Vol. 5 No. 1 (2019): Current Issue
Research Article

Phase I/II Clinical Trial of Weekly Intraperitoneal Paclitaxel (IP-PTX) with Monthly Intravenous Carboplatin (IV-CBDCA) for Minimal Residual Disease of Ovarian, Tubal, and Peritoneal Carcinoma

Takeuchi S
Department of Gynecology, Division of Gynecologic Oncology, Kobe Tokushukai Hospital, Women’s Health Care, Japan
Terai Y
National Hospital Organization, Kobe Medical Center Obstetrics and Gynecology, Japan
Tanimura K
National Hospital Organization, Kobe Medical Center Obstetrics and Gynecology, Japan
Miyamoto T
Department of Gynecology and Obstetrics, Kakogawa Central City Hospital, Japan
Omichi M
Department of Gynecology and Obstetrics, Osaka Medical College, Japan
Takeuchi K
National Hospital Organization, Kobe Medical Center Obstetrics and Gynecology, Japan
Published June 11, 2019


We conducted weekly intraperitoneal administration of paclitaxel (IP-PTX) with monthly intravenous administration of carboplatin (IV-CBDCA), as a prospective phase 1/2 setting. The purpose of this study was to assess the pharmacokinetics and to decide the recommended dose (RD) according to modified Fibonacci method. Patients aged 20-75 years old with histological confirmed mullerian cancers (epithelial ovarian cancer; EOC, fallopian tubal cancer; FTC, and primary peritoneal cancer; PPC) from stage IC to IV or the patients with recurrent disease with small residual disease (including retention of ascetic fluid, para-aortic nodes recurrence after optimal debulked after interval debulking surgery; IDS) were eligible. The protocol regimen consisted of IP-PTX on day1 (D1), 8, and 15, at a starting dose level 1(DL1) of 45 mg/m2, with 15 mg/ m2 incremental, and IV-CBDCA was fixed dose AUC 5.0 mg/mL.min on D1, monthly. The accrual period was from August 2000 until September 2005. As for result, twelve patients were enrolled. No dose limiting toxicity (DLT) was observed in DL1. In dose level 2 (DL2, 60 mg/m2), one grade 3 (G3) hypersensitive reaction to CBDCA was detected. Further 5 patients had been enrolled but additional DLT was not identified. The RD was decided as DL2, which was the same dose of RD in weekly IP-PTX reported by Francis et al. The serum AUCs of PTX in DL1 and DL2 were 1605 nM.min and 2365 nM.min, respectively. By serum CA125, five complete responses were observed out of 8 evaluable patients by Rustin’s criteria. In conclusion, the combination of weekly IP-PTX and monthly IV-CBDCA at AUC 5.0 mg/mL.min was feasible and the recommended dose of IP-PTX was 60 mg/m2. The therapy was moderate effective for optimal debulking mullerian carcinomas. From our pharmacokinetic results, as for the patients with extra-pelvic lesions, additional IV-PTX would be necessary like GOG 172 experimental arm.